Petit 1996.

Methods	Allocation: randomised ‐ no further details.* Blinding: double ‐ identical and dummy capsules. Duration: 8 weeks ‐ preceded by omission of last depot. Intention‐to‐treat analysis: last observation carried forward. Setting: 13 French hospitals. Power calculation: able to demonstrate an 8.2 difference between treatment groups on BPRS.
Participants	Diagnosis: schizophrenia (DSM‐III‐R). Inclusion criteria: 4+ on CGI, not physically ill, no substance abuse. N=126. Age: range 18‐68 years, mean ˜39. Sex: 63 M, 63 F.* History: currently acutely ill, in hospital, overall duration ill 6 months to 41 years.
Interventions	1. Zotepine: dose 150‐300 mg/day. N=63. 2. Haloperidol: dose 10‐20 mg/day. N=63.
Outcomes	Mental state (50% reduction in BPRS). Leaving the study early. Adverse events. Unable to use ‐ Global improvement (CGI ‐ no mean). Mental state (SANS ‐ no mean). Adverse events: (AIMS, SAS ‐ no SD). ECG (no data). Pulse (no SD).
Notes	* Haloperidol group had twice as many women as zotepine group.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear